World Journal of Urology

, Volume 33, Issue 10, pp 1467–1473 | Cite as

The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients

  • Eva-Maria Thurner
  • Sabine Krenn-Pilko
  • Uwe Langsenlehner
  • Tatjana Stojakovic
  • Martin Pichler
  • Armin Gerger
  • Karin S. Kapp
  • Tanja LangsenlehnerEmail author
Original Article



Fibrinogen plays an important role in the pathophysiology of tumour cell invasion and metastases. In recent studies, an elevated plasma fibrinogen level has been associated with poor prognosis in different types of cancer. The present study was performed to analyse the prognostic impact of an elevated fibrinogen level in prostate cancer patients.


We evaluated data from 268 prostate cancer patients who underwent 3D conformal radiotherapy between 1999 and 2006 at a single tertiary academic center. Cancer-specific survival (CSS), overall survival (OS), and clinical disease-free survival (DFS) were assessed using the Kaplan–Meier method. Univariable and multivariable Cox regression models were performed for each endpoint.


Applying receiver operating characteristics (ROC) curve analysis, the optimal cut-off level for the plasma fibrinogen level was 530 mg dl−1, respectively. Univariable (HR 3.638, 95 % CI 1.15–11.47, p = 0.027) and multivariable analyses (HR 3.964, 95 % CI 1.06–14.87, p = 0.041) revealed a significant correlation between increased plasma fibrinogen and CSS. Univariable analysis also showed a significant association between the elevated plasma fibrinogen level and decreased OS (HR 3.242, 95 % CI 1.53–6.89, p = 0.002), that remained significant in multivariable analysis (HR 3.215, 95 % CI 1.44–7.19, p = 0.004). No significant associations were found for clinical DFS.


Although our data show a significant association between an elevated plasma fibrinogen level and poor prostate cancer prognosis, they have to be interpreted cautiously. Limitations of the present study are caused by its retrospective design, the limited accuracy obtained using ROC curve analysis, and potential confounding factors like cardiovascular disease and inflammatory diseases that have not been accounted for.


Prostate cancer Radiotherapy Prognosis Coagulation Fibrinogen 


Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

The study complied with the Declaration of Helsinki and has been approved by the local Ethical Committee.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Palumbo JS (2008) Mechanisms linking tumour cell-associated procoagulant function to tumour dissemination. Semin Thromb Hemost 34:154–160CrossRefPubMedGoogle Scholar
  3. 3.
    Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumour growth, invasion, and metastasis. Cell Mol Life Sci 57:25–40CrossRefPubMedGoogle Scholar
  4. 4.
    Brown LF, Van de Water L, Harvey VS, Dvorak HF (1988) Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumour stroma. Am J Pathol 130:455–465PubMedCentralPubMedGoogle Scholar
  5. 5.
    Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW (2008) Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 6:176–183CrossRefPubMedGoogle Scholar
  6. 6.
    Wojtukiewicz MZ, Sierko E, Rak J (2004) Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 30:5–20CrossRefPubMedGoogle Scholar
  7. 7.
    Daly ME, Makris A, Reed M, Lewis CE (2003) Hemostatic regulators of tumour angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 95:1660–1673CrossRefPubMedGoogle Scholar
  8. 8.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309PubMedGoogle Scholar
  10. 10.
    Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S (2007) Pretreatment plasma fibrinogen level correlates with tumour progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 22:2222–2227CrossRefPubMedGoogle Scholar
  11. 11.
    Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H (2006) Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Guo Q, Zhang B, Dong X, Xie Q, Guo E, Huang H, Wu Y (2009) Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 38:e75–e79CrossRefPubMedGoogle Scholar
  13. 13.
    Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J (2010) High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 102:428–432CrossRefPubMedGoogle Scholar
  14. 14.
    Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979–985CrossRefPubMedGoogle Scholar
  15. 15.
    Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L (2009) Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 200:647.e1–647.e7CrossRefGoogle Scholar
  16. 16.
    Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L (2010) The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 102:952–956PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Pichler M, Hutterer GC, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R (2013) High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 109:1123–1129. doi: 10.1038/bjc.2013.443 PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Pichler M, Dalpiaz O, Ehrlich GC, Stojakovic T, Martín Hernández JM, Mannweiler S, Pummer K, Zigeuner R, Hutterer GC (2013) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191:920–925. doi: 10.1016/j.juro.2013.10.073 CrossRefPubMedGoogle Scholar
  19. 19.
    Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, Hao S, Zeng X (2009) Platelets and fibrinogen facilitate each other in protecting tumour cells from natural killer cytotoxicity. Cancer Sci 100:859–865CrossRefPubMedGoogle Scholar
  20. 20.
    Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res 70:2634–2643. doi: 10.1158/0008-5472.CAN-09-3465 PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Ziaran S, Goncalves FM, Breza J Sr (2013) Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol 31:289–292. doi: 10.1007/s00345-012-0926-x CrossRefPubMedGoogle Scholar
  22. 22.
    Seal US, Doe RP, Byar DP, Corle DK (1976) Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer 38:1108–1117CrossRefPubMedGoogle Scholar
  23. 23.
    McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E (2014) Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease—the 2001–2008 National Health and Nutrition Examination Survey. Prostate 74:561–567. doi: 10.1002/pros.22782 PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Tiedje V, Dunkler D, Ay C, Horvath B, Quehenberger P, Pabinger M, Zielinski C, Pabinger I, Mannhalter C (2011) The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost 106:908–913. doi: 10.1160/TH11-04-0278 CrossRefPubMedGoogle Scholar
  25. 25.
    Song SW, Lee HS, Kim MS, Lee JM, Kim JH, Nam BH, Zo JI (2006) Preoperative serum fibrinogen level predicts postoperative pulmonary complications after lung cancer resection. Ann Thorac Surg 81:1974–1981CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Eva-Maria Thurner
    • 1
  • Sabine Krenn-Pilko
    • 1
  • Uwe Langsenlehner
    • 2
  • Tatjana Stojakovic
    • 3
  • Martin Pichler
    • 4
  • Armin Gerger
    • 4
  • Karin S. Kapp
    • 1
  • Tanja Langsenlehner
    • 1
    Email author
  1. 1.Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center GrazMedical University of GrazGrazAustria
  2. 2.Division of Internal MedicineOutpatient Department GrazGrazAustria
  3. 3.Clinical Institute of Medical and Chemical Laboratory DiagnosticsMedical University of GrazGrazAustria
  4. 4.Division of Clinical Oncology, Department of MedicineMedical University of GrazGrazAustria

Personalised recommendations